e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2010
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware   1-33734   94-3200380
         
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
     
4939 Directors Place   92121
San Diego, California   (Zip Code)
(Address of principal executive offices)    
Registrant’s telephone number, including area code: (858) 652-6500
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

TABLE OF CONTENTS
         
Item 7.01. Regulation FD Disclosure
       
Item 9.01. Financial Statements and Exhibits
       
SIGNATURE
       
EXHIBIT LIST
       
EXHIBIT 99.1
       

 


 

Item 7.01. Regulation FD Disclosure
Ardea Biosciences, Inc. (the “Company”) has recently received and publicly announced certain clinical data related to its products. A copy of the press release announcing the data is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.
The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
     
Exhibit    
Number   Document Description
99.1
  Press release dated January 7, 2010.

 


 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
  ARDEA BIOSCIENCES, INC.
 
 
Date: January 7, 2010  /s/ CHRISTIAN WAAGE    
  Christian Waage   
  General Counsel   
 

 


 

EXHIBIT LIST
     
Exhibit    
Number   Document Description
99.1
  Press release dated January 7, 2010.